According to the latest report by IMARC Group, titled "Lung Marker Market Report by Cancer Type (Non-Small Cell Lung Cancer (NSCLC), Small Cell Lung Cancer (SCLC)), Marker Type (EGFR, EML4-ALK, KRAS, BRAF, and Others), End User (Hospitals, Diagnostic Labs, and Others), and Region 2025-2033," the global lung marker market reached a value of USD 482.2 Million in 2024. Lung markers are substances produced by tumor cells that are used for lung localization. They are produced in the body in response to cancer and are found in the urine, blood and stool of the patients. They are used during lung intervention procedures for providing information regarding the nature and condition of cancer. They also aid in diagnosing, predicting and monitoring the tumor for understanding the type of therapy required to treat the condition. Apart from this, they are used in numerous hospitals and other healthcare facilities in the diagnosis and treatment of pleural effusion and mesothelioma.
Global Lung Marker Market Trends:
The global market is primarily driven by the increasing prevalence of lung cancer and the high mortality rates associated with it. This has led the key players to heavily invest in research and development (R&D) for the introduction of an effective cure. Since lung markers form an indispensable component in lung localization, a significant increase in their demand has been registered. Along with this, there has been an increase in the occurrence of respiratory disorders on account of deteriorating air quality, unhealthy lifestyle preferences and high smoking rates among the masses. Furthermore, the growing geriatric population across the globe is vulnerable to develop acute respiratory disorders, which is propelling the demand for lung markers. Governments of several countries are also offering numerous healthcare benefits for the early diagnosis and pre-treatment of several chronic diseases, such as lung cancer, which is acting as another major growth-inducing factor. Looking forward, the market value is projected to reach USD 1,104.6 Million by 2033, expanding at a CAGR of 9.6% during 2025-2033.
Market Summary:
Report Features | Details |
---|---|
Base Year of the Analysis | 2024 |
Historical Period | 2019-2024 |
Forecast Period | 2025-2033 |
Units | Million USD |
Segment Coverage | Cancer Type, Marker Type, End-User, Region |
Region Covered | Asia Pacific, Europe, North America, Latin America, Middle East and Africa |
Countries Covered | United States, Canada, Germany, France, United Kingdom, Italy, Spain, Russia, China, Japan, India, South Korea, Australia, Indonesia, Brazil, Mexico, Argentina, Colombia, Chile, Peru, Turkey, Iran |
Companies Covered | Abbott Laboratories, Thermo Fisher Scientific Inc., Agilent Technologies, Inc., Beckman Coulter, Inc., Fujirebio Europe N.V., Hologic, Inc., F. Hoffmann-La Roche Ltd, Siemens Healthineers, and BioSpace, Inc. |
Customization Scope | 10% Free Customization |
Post-Sale Analyst Support | 10-12 Weeks |
Delivery Format | PDF and Excel through Email (We can also provide the editable version of the report in PPT/Word format on special request) |
About Us:
IMARC Group is a leading market research company that offers management strategy and market research worldwide. We partner with clients in all sectors and regions to identify their highest-value opportunities, address their most critical challenges, and transform their businesses.
IMARC’s information products include major market, scientific, economic and technological developments for business leaders in pharmaceutical, industrial, and high technology organizations. Market forecasts and industry analysis for biotechnology, advanced materials, pharmaceuticals, food and beverage, travel and tourism, nanotechnology and novel processing methods are at the top of the company’s expertise.
Contact Us:
IMARC Group
USA: +1-631-791-1145
Email: sales@imarcgroup.com
Website: https://www.imarcgroup.com
Follow us on twitter: @imarcglobal